Human receptor epidermal growth factor 2 (HER2, also known as ERBB2) gene amplification is shown to drive tumor development and progression in 18–26% of patients with mucinous ovarian carcinoma.20 A case report described a patient with metastatic mucinous ovarian carcinoma treated previously with surgical resection, chemotherapy, bevacizumab and cetuximab with disease progression. Here, ERBB2 is linked to neoplasm.